Targeting the thyroid-stimulating hormone receptor with small molecule ligands and antibodies

Expert Opinion on Therapeutic Targets

Volumn 19, Issue 6, 2015, Pages 835-847

  Davies, Terry F ^a   Latif, Rauf ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Autoantibodies; Glycoprotein hormone receptor; Graves' disease; Small molecule ligands; Thyroid cancer; Thyroid stimulating hormone receptor

Indexed keywords

2 [3 (2,6 DIMETHYLPHENYLTHIO) 4 METHOXYPHENYL] (FURAN 2 YLMETHY) 2,3 DIHYDROQUINAZOLIN 4(1H) ONE; 2 [3 [(2,6 DIMETHYLPHENOXY)METHYL] 4 METHOXYPHENYL] 3 (FURAN 2 YLMETHYL) 2,3 DIHYDROQUINAZOLIN 4(1H) ONE; 2 [3 [(2,6 DIMETHYLPHENOXY)METHYL] 4 METHOXYPHENYL] 3 (PYRIDIN 2 YLMETHYL) 2,3 DIHYDROQUINAZOLIN 4(1H) ONE; BENZYL6METHYL 2 OXO 4 [4 (TRIFLUOROMETHYL)PHENYL] 1,2,3,4 TETRAHYDRO 5 PYRIMIDINEVARBOXYLATE; HORMONE RECEPTOR BLOCKING AGENT; HORMONE RECEPTOR STIMULATING AGENT; MONOCLONAL ANTIBODY; N (1 ACETYL 4 METHYL 4 PHENYL 1,2,3,4 TETRAHYDRO-QUINOLIN 6 YL) 3 (3 TRIFLUOROMETHYLPHENYL)PROPIONAMIDE; N 4 [4 [5 (3 BENZYL 5 HYDROOXY 4 OX) 1,2,3,4 TETRAHYDROQUINAZOLIN 2 YL] 2 METHOXYBENZYLOXY]ACETAMIDE; N TERTBUTYL 5 AMINO 4 (3 METHOXYPHENYL) 2 (METHYLTHIO)THIENO[2,3 D]PYRIMIDINE 6 CARBOXAMIDE; N [4 [5 [3 (FURAN 2 YLMETHYL) 4 OXO 1,2,3,4 TETRAHYDROQUINAZOLIN 2 YL] 2 METHOXYBENZYLOXY] 3,5 DIMETHYLPHENYL]ACETAMIDE; N,N DIISOPROPYL 2 PHENYL 4 QUINOLINECARBOXAMIDE; NCG00161870; SMALL MOLECULE TRANSPORT AGENT; THYROID STIMULATING HORMONE RECEPTOR AGONIST; THYROID STIMULATING HORMONE RECEPTOR ANTAGONIST; THYROTROPIN RECEPTOR; THYROTROPIN RECEPTOR ANTIBODY; UNCLASSIFIED DRUG; ANTIBODY; AUTOANTIGEN; LIGAND;

ALLOSTERISM; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; HUMAN; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN STABILITY; PROTEIN STRUCTURE; REVIEW; THYROID FUNCTION; ANIMAL; DRUG DESIGN; GRAVES DISEASE; IMMUNOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; THYROID NEOPLASMS;

ANIMALS; ANTIBODIES; AUTOANTIGENS; DRUG DESIGN; GRAVES DISEASE; HUMANS; LIGANDS; MOLECULAR TARGETED THERAPY; RECEPTORS, THYROTROPIN; SIGNAL TRANSDUCTION; THYROID NEOPLASMS;

EID: 84929575459     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2015.1018181     Document Type: Review

References (95)

1. Caltabiano G, Campillo M, De Leener A, et al. The specificity of binding of glycoprotein hormones to their receptors. Cell Mol Life Sci 2008;65(16):2484-92
2. Vassart G, Costagliola S. G proteincoupled receptors: mutations and endocrine diseases. Nat Rev Endocrinol 2011;7(6):362-72
3. Adams DD, Purves HD. The role of thyrotrophin in hyperthyroidism and exophthalmos. Metabolism 1957;6(1):26-35
4. Smith BR, Hall R. Thyroid-stimulating immunoglobulins in Graves' disease. Lancet 1974;2(7878):427-31
5. Rapoport B, Chazenbalk GD, Jaume JC, et al. The thyrotropin (TSH) receptor: interaction with TSH and autoantibodies. Endocr Rev 1998;19(6):673-716
6. Kleinau G, Neumann S, Gruters A, et al. Novel insights on thyroid-stimulating hormone receptor signal transduction. Endocr Rev 2013;34(5):691-724
7. Kriss JP, Pleshakov V, Chien JR. Isolation and identification of the long-acting thyroid stimulator and its relation to hyperthyroidism and circumscribed pretibial myxedema. J Clin Endocrinol Metab 1964;24:1005-28
8. Jeffreys J, Depraetere H, Sanders J, et al. Characterization of the thyrotropin binding pocket. Thyroid 2002;12(12):1051-61
9. Sanders J, Chirgadze DY, Sanders P, et al. Crystal structure of the TSH receptor in complex with a thyroidstimulating autoantibody. Thyroid 2007;17(5):395-410
10. Biebermann H, Winkler F, Kleinau G. Genetic defects, thyroid growth and malfunctions of the TSHR in pediatric patients. Front Biosci 2010;15:913-33
11. Wonerow P, Neumann S, Gudermann T, et al. Thyrotropin receptor mutations as a tool to understand thyrotropin receptor action. J Mol Med 2001;79(12):707-21
12. Jiang X, Fischer D, Chen X, et al. Evidence for Follicle-stimulating Hormone Receptor as a Functional Trimer. J Biol Chem 2014;289(20):14273-82
13. Mizutori Y, Chen CR, McLachlan SM, et al. The thyrotropin receptor hinge region is not simply a scaffold for the leucine-rich domain but contributes to ligand binding and signal transduction. Mol Endocrinol 2008;22(5):1171-82
14. Kosugi S, Mori T. Cysteine-699, a possible palmitoylation site of the thyrotropin receptor, is not crucial for cAMP or phosphoinositide signaling but is necessary for full surface expression. Biochem Biophys Res Commun 1996;221(3):636-40
15. Tanaka K, Nagayama Y, Nishihara E, et al. Palmitoylation of human thyrotropin receptor: slower intracellular trafficking of the palmitoylation-defective mutant. Endocrinology 1998;139(2):803-6
16. Tanaka K, Chazenbalk GD, McLachlan SM, et al. The shed thyrotropin receptor is primarily a carboxyl terminal truncated form of the A subunit, not the entire A subunit. Mol Cell Endocrinol 1999;150(1-2):113-19
17. Latif R, Graves P, Davies TF. Oligomerization of the human thyrotropin receptor: fluorescent proteintagged hTSHR reveals post-translational complexes. J Biol Chem 2001;276(48):45217-24
18. Urizar E, Montanelli L, Loy T, et al. Glycoprotein hormone receptors: link between receptor homodimerization and negative cooperativity. EMBO J 2005;24(11):1954-64
19. Kursawe R, Paschke R. Modulation of TSHR signaling by posttranslational modifications. Trends Endocrinol Metab 2007;18(5):199-207
20. Latif R, Michalek K, Davies TF. Subunit interactions influence TSHR multimerization. Mol Endocrinol 2010;24(10):2009-18
21. Latif R, Ali MR, Mezei M, Davies TF. Transmembrane domains of attraction on the TSH receptor. Endocrinology 2015;156(2):488-98
22. Calebiro D, de Filippis T, Lucchi S, et al. Intracellular entrapment of wildtype TSH receptor by oligomerization with mutants linked to dominant TSH resistance. Hum Mol Genet 2005;14(20):2991-3002
23. Allen MD, Neumann S, Gershengorn MC. Occupancy of both sites on the thyrotropin (TSH) receptor dimer is necessary for phosphoinositide signaling. FASEB J 2011;25(10):3687-94
24. Graves PN, Vlase H, Davies TF. Folding of the recombinant human thyrotropin (TSH) receptor extracellular domain: identification of folded monomeric and tetrameric complexes that bind TSH receptor autoantibodies. Endocrinology 1995;136(2):521-7
25. Latif R, Ando T, Davies TF. Lipid rafts are triage centers for multimeric and monomeric thyrotropin receptor regulation. Endocrinology 2007;148(7):3164-75
26. Frenzel R, Voigt C, Paschke R. The human thyrotropin receptor is predominantly internalized by β-arrestin 2. Endocrinology 2006;147(6):3114-22.
27. Werthmann RC, Volpe S, Lohse MJ, et al. Persistent cAMP signaling by internalized TSH receptors occurs in thyroid but not in HEK293 cells. FASEB J 2012;26(5):2043-8
28. Calebiro D, Nikolaev VO, Gagliani MC, et al. Persistent cAMP-signals triggered by internalized G-protein-coupled receptors. PLoS Biol 2009;7(8):e1000172
29. Chazenbalk GD, Nagayama Y, Kaufman KD, et al. The functional expression of recombinant human thyrotropin receptors in nonthyroidal eukaryotic cells provides evidence that homologous desensitization to thyrotropin stimulation requires a cell-specific factor. Endocrinology 1990;127(3):1240-4
30. Nagayama Y, Chazenbalk GD, Takeshita A, et al. Studies on homologous desensitization of the thyrotropin receptor in 293 human embryonal kidney cells. Endocrinology 1994;135(3):1060-5
31. Zhang M, Tong KP, Fremont V, et al. The extracellular domain suppresses constitutive activity of the transmembrane domain of the human TSH receptor: implications for hormonereceptor interaction and antagonist design. Endocrinology 2000;141(9):3514-17
32. Zaballos MA, Garcia B, Santisteban P. Gbetagamma dimers released in response to thyrotropin activate phosphoinositide 3-kinase and regulate gene expression in thyroid cells. Mol Endocrinol 2008;22(5):1183-99
33. Allgeier A, Offermanns S, Van Sande J, et al. The human thyrotropin receptor activates G-proteins Gs and Gq/11. J Biol Chem 1994;269(19):13733-5
34. Laurent E, Mockel J, Van Sande J, et al. Dual activation by thyrotropin of the phospholipase C and cyclic AMP cascades in human thyroid. Mol Cell Endocrinol 1987;52(3):273-8
35. Morshed SA, Latif R, Davies TF. Characterization of thyrotropin receptor antibody-induced signaling cascades. Endocrinology 2009;150(1):519-29
36. Garcia-Jimenez C, Santisteban P. TSH signalling and cancer. Arq Bras Endocrinol Metabol 2007;51(5):654-71
37. Russo D, Nagayama Y, Chazenbalk GD, et al. Role of amino acids 261-418 in proteolytic cleavage of the extracellular region of the human thyrotropin receptor. Endocrinology 1992;130(4):2135-8
38. Wadsworth HL, Russo D, Nagayama Y, et al. Studies on the role of amino acids 38-45 in the expression of a functional thyrotropin receptor. Mol Endocrinol 1992;6(3):394-8
39. Wadsworth HL, Chazenbalk GD, Nagayama Y, et al. An insertion in the human thyrotropin receptor critical for high affinity hormone binding. Science 1990;249(4975):1423-5
40. Chazenbalk GD, Jaume JC, McLachlan SM, et al. Engineering the human thyrotropin receptor ectodomain from a non-secreted form to a secreted, highly immunoreactive glycoprotein that neutralizes autoantibodies in Graves' patients' sera. J Biol Chem 1997;272(30):18959-65
41. Loosfelt H, Pichon C, Jolivet A, et al. Two-subunit structure of the human thyrotropin receptor. Proc Natl Acad Sci USA 1992;89(9):3765-9
42. Couet J, de Bernard S, Loosfelt H, et al. Cell surface protein disulfide-isomerase is involved in the shedding of human thyrotropin receptor ectodomain. Biochemistry 1996;35(47):14800-5
43. Couet J, Sar S, Jolivet A, et al. Shedding of human thyrotropin receptor ectodomain. Involvement of a matrix metalloprotease. J Biol Chem 1996;271(8):4545-52
44. Latif R, Ando T, Davies TF. Monomerization as a prerequisite for intramolecular cleavage and shedding of the thyrotropin receptor. Endocrinology 2004;145(12):5580-8
45. Misrahi M, Couet J, Milgrom E. Mechanisms of shedding of a soluble form of the TSH receptor. Ann Endocrinol (Paris) 1997;58(5):365-9
46. Boelaert K. Thyroid gland: revised guidelines for the management of thyroid cancer. Nat Rev Endocrinol 2010;6(4):185-6
47. Boelaert K. Treatment of Graves' disease with antithyroid drugs: current perspectives. Thyroid 2010;20(9):943-6
48. Galofre JC, Duntas LH, Premawardhana LD, et al. Advances in graves' disease. J Thyroid Res 2012;2012:809231
49. Bahn RS, Burch HS, Cooper DS, et al. The Role of Propylthiouracil in the Management of Graves' Disease in Adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration. Thyroid 2009;19(7):673-4
50. Karlsson FA, Axelsson O, Melhus H. Severe embryopathy and exposure to methimazole in early pregnancy. J Clin Endocrinol Metab 2002;87(2):947-9
51. Bahn RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr Pract 2011;17(3):456-520
52. Haugen BR, Pacini F, Reiners C, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999;84(11): 3877-85
53. Huber GK, Fong P, Concepcion ES, et al. Recombinant human thyroidstimulating hormone: initial bioactivity assessment using human fetal thyroid cells. J Clin Endocrinol Metab 1991;72(6):1328-31
54. Ladenson PW, Braverman LE, Mazzaferri EL, et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma [see comments]. N Engl J Med 1997;337(13):888-96
55. Mazzaferri EL, Kloos RT. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab 2002;87(4):1490-8
56. Mueller S, Kleinau G, Szkudlinski MW, et al. The superagonistic activity of bovine thyroid-stimulating hormone (TSH) and the human TR1401 TSH analog is determined by specific amino acids in the hinge region of the human TSH receptor. J Biol Chem 2009;284(24):16317-24
57. Guo T. Small molecule agonists and antagonists for the LH and FSH receptors. Expert Opinion Ther Targets 2005;15(11):1555-63
58. Jaschke H, Neumann S, Moore S, et al. A low molecular weight agonist signals by binding to the transmembrane domain of thyroid-stimulating hormone receptor (TSHR) and luteinizing hormone/chorionic gonadotropin receptor (LHCGR). J Biol Chem 2006;281(15):9841-4
59. Neumann S, Huang W, Titus S, et al. Small-molecule agonists for the thyrotropin receptor stimulate thyroid function in human thyrocytes and mice. Proc Natl Acad Sci USA 2009;106(30):12471-6
60. Latif R, Ali MR, Ma R, et al. New small molecule agonists to the thyrotropin receptor. Thyroid 2015;25(1):51-62
61. Kleinau G, Haas AK, Neumann S, et al. Signaling-sensitive amino acids surround the allosteric ligand binding site of the thyrotropin receptor. FASEB J 2010;24(7):2347-54
62. Rossi M, Dimida A, Dell'anno MT, et al. The thyroid disruptor 1,1,1-trichloro-2,2-bis(p-chlorophenyl)-ethane appears to be an uncompetitive inverse agonist for the thyrotropin receptor. J Pharmacol Exp Ther 2007;320(1):465-74
63. Rossi M, Dimida A, Ferrarini E, et al. Presence of a putative steroidal allosteric site on glycoprotein hormone receptors. Eur J Pharmacol 2009;623(1-3):155-9
64. Neumann S, Kleinau G, Costanzi S, et al. A low-molecular-weight antagonist for the human thyrotropin receptor with therapeutic potential for hyperthyroidism. Endocrinology 2008;149(12):5945-50
65. van Koppen CJ, Zaman GJ, Timmers CM, et al. A signaling-selective, nanomolar potent allosteric low molecular weight agonist for the human luteinizing hormone receptor. Naunyn Schmiedebergs Arch Pharmacol 2008;378(5):503-14
66. Neumann S, Eliseeva E, McCoy JG, et al. A new small-molecule antagonist inhibits Graves' disease antibody activation of the TSH receptor. J Clin Endocrinol Metab 2011;96(2):548-54
67. Neumann S, Pope A, Geras-Raaka E, et al. A drug-like antagonist inhibits thyrotropin receptor-mediated stimulation of cAMP production in Graves' orbital fibroblasts. Thyroid 2012;22(8):839-43
68. Rees Smith B, Sanders J, Evans M. TSH receptor - autoantibody interactions. Horm Metab Res 2009;41(6):448-55
69. Nunez Miguel R, Sanders J, Chirgadze DY, et al. Thyroid stimulating autoantibody M22 mimics TSH binding to the TSH receptor leucine rich domain: a comparative structural study of protein-protein interactions. J Mol Endocrinol 2009;42(5):381-95
70. Benovic JL. G-protein-coupled receptors signal victory. Cell 2012;151(6):1148-50
71. Audet M, Bouvier M. Restructuring G-protein-coupled receptor activation. Cell 2012;151(1):14-23
72. Davies TF, Ali MR, Latif R. Allosteric modulators hit the TSH receptor. Endocrinology 2014;155(1):1-5
73. Haas AK, Kleinau G, Hoyer I, et al. Mutations that silence constitutive signaling activity in the allosteric ligandbinding site of the thyrotropin receptor. Cell Mol Life Sci 2011;68(1):159-67
74. Davies T, Marians R, Latif R. The TSH receptor reveals itself. J Clin Invest 2002;110(2):161-4
75. Morshed SA, Ando T, Latif R, Davies TF. Neutral antibodies to the TSH receptor are present in Graves' disease and regulate selective signaling cascades. Endocrinology 2010;151(11):5537-49
76. Sanders P, Young S, Sanders J, et al. Crystal structure of the TSH receptor (TSHR) bound to a blocking-type TSHR autoantibody. J Mol Endocrinol 2011;46(2):81-99
77. Morshed SA, Latif R, Davies TF. Delineating the autoimmune mechanisms in Graves' disease. Immunol Res 2012;54(1-3):191-203
78. Vlase H, Graves PN, Magnusson RP, et al. Human autoantibodies to the thyrotropin receptor: recognition of linear, folded, and glycosylated recombinant extracellular domain. J Clin Endocrinol Metab 1995;80(1):46-53
79. Mori T, Sugawa H, Piraphatdist T, et al. A synthetic oligopeptide derived from human thyrotropin receptor sequence binds to Graves' immunoglobulin and inhibits thyroid stimulating antibody activity but lacks interactions with TSH. Biochem Biophys Res Commun 1991;178(1):165-72
80. Endo T, Ohmori M, Ikeda M, et al. Heterogeneous responses of recombinant human thyrotropin receptor to immunoglobulins from patients with Graves' disease. Biochem Biophys Res Commun 1992;186(3):1391-6
81. Nagy EV, Burch HB, Mahoney K, et al. Graves' IgG recognizes linear epitopes in the human thyrotropin receptor. Biochem Biophys Res Commun 1992;188(1):28-33
82. Takai O, Desai RK, Seetharamaiah GS, et al. Prokaryotic expression of the thyrotropin receptor and identification of an immunogenic region of the protein using synthetic peptides. Biochem Biophys Res Commun 1991;179(1):319-26
83. Ando T, Latif R, Pritsker A, et al. A monoclonal thyroid-stimulating antibody. J Clin Invest 2002;110(11):1667-74
84. Sanders J, Evans M, Premawardhana LD, et al. Human monoclonal thyroid stimulating autoantibody. Lancet 2003;362(9378):126-8
85. Abe E, Marians RC, Yu W, et al. TSH is a negative regulator of skeletal remodeling. Cell 2003;115(2):151-62
86. Kumar S, Nadeem S, Stan MN, et al. A stimulatory TSH receptor antibody enhances adipogenesis via phosphoinositide 3-kinase activation in orbital preadipocytes from patients with Graves' ophthalmopathy. J Mol Endocrinol 2011;46(3):155-63
87. Lu M, Lin RY. TSH stimulates adipogenesis in mouse embryonic stem cells. J Endocrinol 2008;196(1): 159-69
88. Bahn RS. TSH receptor expression in orbital tissue and its role in the pathogenesis of Graves' ophthalmopathy. J Endocrinol Invest 2004;27(3): 216-20
89. Rees Smith B, Nordmeyer P, Sanders J, et al. Eye signs of graves' disease and blocking-type thyrotropin receptor autoantibodies. Thyroid 2006;16(1):97-8
90. Hansen C, Rouhi R, Forster G, et al. Increased sulfatation of orbital glycosaminoglycans in Graves' ophthalmopathy. J Clin Endocrinol Metab 1999;84(4):1409-13
91. Bahn RS. Graves' ophthalmopathy. N Engl J Med 2010;362(8):726-38
92. Paolino D, Cosco D, Gaspari M, et al. Targeting the thyroid gland with thyroid-stimulating hormone (TSH)-nanoliposomes. Biomaterials 2014;35(25):7101-9
93. Neumann S, Nir EA, Eliseeva E, et al. A selective TSH receptor antagonist inhibits stimulation of thyroid function in female mice. Endocrinology 2014;155(1):310-14
94. van Koppen CJ, de Gooyer ME, Karstens WJ, et al. Mechanism of action of a nanomolar potent, allosteric antagonist of the thyroid-stimulating hormone receptor. Br J Pharmacol 2012;165(7):2314-24
95. Davies TF, Yin X, Latif R. The genetics of the thyroid stimulating hormone receptor: history and relevance. Thyroid 2010;20(7):727-36